Incyte Corporation is a biopharmaceutical company specializing in the discovery, development, and commercialization of innovative therapies for the treatment of various diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and has emerged as a significant player in the field of oncology and immunology.
Incyte is dedicated to advancing medical science and improving patient outcomes through the development of targeted therapies. The company's primary focus lies in the research and development of small molecule drugs that target specific pathways involved in diseases such as cancer and autoimmune disorders. Their approach involves utilizing genomic analysis to identify potential drug targets and then designing and developing targeted therapies.
One of Incyte's most well-known products is Jakafi® (ruxolitinib), which is approved for the treatment of certain types of blood cancers and myeloproliferative neoplasms. Jakafi is a JAK1/JAK2 inhibitor that works by targeting specific signaling pathways involved in the development of these diseases. It has been proven to provide significant clinical benefits for patients.
Incyte went public in 1993 and has since expanded its portfolio through internal research and development as well as strategic collaborations and partnerships. The company has forged alliances with various pharmaceutical companies and academic institutions to accelerate the discovery and development of new therapies. They continue to invest in research and clinical trials to explore the potential of their pipeline candidates in treating other diseases and expanding their therapeutic areas of focus.